Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae365 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Rebecca Clark und 17 weiteren Autor:innen. Beteiligte Einrichtung: Layton Medical Centre, Blackpool, United Kingdom. Hauptthemen laut MEDLINE: Influenza Vaccines, Antibodies, Viral, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
We evaluated co-administration of adjuvanted seasonal quadrivalent influenza vaccine (FLU-aQIV) and respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) in ≥65-year-olds.
Methods
This phase 3, open-label trial randomized ≥65-year-olds to receive FLU-aQIV and RSVPreF3 OA concomitantly (Co-Ad) or sequentially, 1 month apart (Control). Primary objectives were to demonstrate the non-inferiority of FLU-aQIV and RSVPreF3 OA co-administration versus sequential administration in terms of hemagglutination inhibition (HI) titers for each FLU-aQIV strain and RSV-A and RSV-B neutralization titers, 1 month post-vaccination. Reactogenicity and safety were also assessed.
Results
Overall, 1045 participants were vaccinated (Co-Ad: 523; Control: 522). Non-inferiority of FLU-aQIV and RSVPreF3 OA co-administration versus sequential administration was demonstrated in terms of HI titers for the A/Victoria(H1N1), B/Victoria, and B/Yamagata influenza strains and RSV-A neutralization titers (upper limits [ULs] of 95% confidence intervals [CIs] for adjusted geometric mean titer [GMT] ratios [Control/Co-Ad] ≤1.50) but not for A/Darwin(H3N2) HI titers (95% CI UL = 1.53). The immune response to A/Darwin(H3N2) was further assessed post-hoc using a microneutralization assay; the post-vaccination adjusted GMT ratio (Control/Co-Ad) was 1.23 (95% CI: 1.06–1.42, ie, UL ≤1.50), suggesting an adequate immune response to A/Darwin(H3N2) following co-administration. RSV-B neutralization titers were comparable between groups (95% CI UL for adjusted GMT ratio ≤1.50). Solicited adverse events were mostly mild or moderate and transient; unsolicited and serious adverse event rates were balanced between groups.
Conclusions
Adjuvanted FLU-aQIV and RSVPreF3 OA had acceptable reactogenicity/safety profiles when co-administered in ≥65-year-olds, without clinically relevant interference with the immune responses to either vaccine. Clinical Trials Registration NCT05568797
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Layton Medical Centre, Blackpool, United Kingdom.
- South Gloucestershire Medical Research Unit, Bristol, United Kingdom.
- Research Unit, Hospital Universitario de Burgos, Burgos, Spain.
- Department of Infectious and Tropical Diseases, VBIC (Bacterial Virulence and Chronic Infection), INSERM, University of Montpellier, CHU Nimes, Nimes, France.
- Unidad de Investigación de Vacunas, Instituto de Investigación Sanitaria HM, Madrid, Spain.
- Departamento de Medicina Preventiva y Salud Pública, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Zitieren
APA
Clark, R., Davies, S., Labrador, J., Loubet, P., Natalini Martínez, S., Moríñigo, H. M., Nicolas, J. F., Vera, M. P., Rämet, M., Rebollo-Rodrigo, M. H., Sanz-Muñoz, I., Dezutter, N., Germain, S., David, M. P., Jayadev, A., Amare Hailemariam, H., Kotb, S., & Meyer, N. (2024). Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae365
Vancouver
Clark R, Davies S, Labrador J, Loubet P, Natalini Martínez S, Moríñigo HM, et al. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae365
BibTeX
@article{Clark2024,
author = {Clark, Rebecca and Davies, Sam and Labrador, Jorge and Loubet, Paul and Natalini Martínez, Silvina and Moríñigo, Helena Moza and Nicolas, Jean-François and Vera, Mercè Pérez and Rämet, Mika and Rebollo-Rodrigo, Maria Henar and Sanz-Muñoz, Iván and Dezutter, Nancy and Germain, Sophie and David, Marie-Pierre and Jayadev, Amulya and Amare Hailemariam, Hiwot and Kotb, Shady and Meyer, Nadia},
title = {Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae365}
}
EUVIMED